首页> 美国卫生研究院文献>Journal of Virology >A TVA–Single-Chain Antibody Fusion Protein Mediates Specific Targeting of a Subgroup A Avian Leukosis Virus Vector to Cells Expressing a Tumor-Specific Form of Epidermal Growth Factor Receptor
【2h】

A TVA–Single-Chain Antibody Fusion Protein Mediates Specific Targeting of a Subgroup A Avian Leukosis Virus Vector to Cells Expressing a Tumor-Specific Form of Epidermal Growth Factor Receptor

机译:TVA单链抗体融合蛋白介导禽白血病病毒亚组对表达肿瘤特异性形式的表皮生长因子受体的细胞的特异性靶向

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We have previously described an approach that employs retroviral receptor-ligand bridge proteins to target retroviral vectors to specific cell types. To determine whether targeted retroviral entry can also be achieved using a retroviral receptor–single-chain antibody bridge protein, the TVA-MR1 fusion protein was generated. TVA-MR1 is comprised of the extracellular domain of the TVA receptor for subgroup A avian leukosis viruses (ALV-A), fused to the MR1 single-chain antibody that binds specifically to EGFRvIII, a tumor-specific form of the epidermal growth factor receptor. We show that TVA-MR1 binds specifically to a murine version of EGFRvIII and promotes ALV-A entry selectively into cells that express this cell surface marker. These studies demonstrate that it is possible to target retroviral vectors to specific cell types through the use of a retroviral receptor–single-chain antibody fusion protein.
机译:先前我们已经描述了一种采用逆转录病毒受体-配体桥蛋白将逆转录病毒载体靶向特定细胞类型的方法。为了确定是否也可以使用逆转录病毒受体-单链抗体桥蛋白实现靶向逆转录病毒的进入,产生了TVA-MR1融合蛋白。 TVA-MR1由A亚型禽白血病病毒(ALV-A)的TVA受体的胞外域组成,融合到与EGFRvIII特异性结合的MR1单链抗体上,EGFRvIII是一种表皮生长因子受体的肿瘤特异性形式。我们显示,TVA-MR1与EGFRvIII的鼠类特异性结合,并选择性地促进ALV-A进入表达该细胞表面标记的细胞。这些研究表明,通过使用逆转录病毒受体-单链抗体融合蛋白,可以将逆转录病毒载体靶向特定的细胞类型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号